Who is sponsoring NCT00502593?

NCT00502593 is sponsored by GlaxoSmithKline.

What drugs are being tested in NCT00502593?

Interventions: Pandemic Influenza Vaccine (GSK1562902A), Fluarix™.

What is the status of NCT00502593?

NCT00502593 is currently COMPLETED.

Last reviewed 2018-10-25 · How we verify

Evaluate Safety & Immunogenicity of a Pandemic Influenza Vaccine (GSK1562902A) in Children

NCT00502593 PHASE2 COMPLETED Results posted

The present study is designed to evaluate in children (aged between 3 and 9 years) the immunogenicity and safety of different antigen doses of the candidate vaccine (GSK1562902A) administered following a two-administration schedule (21 days apart). Subjects in the control group will receive Fluarix. The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007.

Details

Lead sponsor	GlaxoSmithKline
Phase	PHASE2
Status	COMPLETED
Enrolment	138
Start date	Mon Jul 23 2007 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Fri Dec 04 2009 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

Influenza

Interventions

Pandemic Influenza Vaccine (GSK1562902A)
Fluarix™

Countries

Spain